Background: In Cameroon, the prevalence of HIV in pregnant
women was 7.8% in 2012, and they were 8500 HIV positive newborns in
2013.Option B+ is the first highly active antiretroviral therapy (HAART)
preventive protocol. The objective was to evaluate the rate of HIV transmission
on children born from mothers who were on Option B+ during pregnancy, in three
university teaching hospitals of the University of Yaoundé I.Methods: It was a retrospective, cross-sectional study over a
period of four years (2013-2017). We included HIV positive mothers not on
previous antiretroviral treatment and who received a single tablet daily of
combined tenofovir(300mg) + Lamivudine (300mg) +
References
[1]
Global Aids Update (2017) Ending AIDS Progress towards the 90-90-90-Targets.
http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf
[2]
UNAIDS (2016) Children and HIV in Fact Sheet. UNAIDS.
http://www.unaids.org/sites/default/files/media_asset/FactSheet_Children_en.pdf
[3]
Billong, S.-C., Fokam, J., Billong, E.-J., Nguefack-Tsague, G., Essi, M.J., Fodjo, R., et al. (2015) Epidemiological Distribution of HIV Infection among Pregnant Women in the Ten Regions of Cameroon and Strategic Implications for Prevention Programs. Pan African Medical Journal, 20, 79-87.
[4]
Nguefack, H., Gwet, H., Desmonde, S., Oukem-Boyer, O., Nkenfou, C., Tejiokem, M., et al. (2016) Estimating Mother-to-Child HIV Transmission Rates in Cameroon in 2011: A Computer Simulation Approach. BMC Infectious Diseases, 16, 11-21.
https://doi.org/10.1186/s12879-016-1336-2
[5]
Adetokunboh, O.O. and Oluwasanu, M. (2016) Eliminating Mother-to-Child Transmission of the Human Immunodeficiency Virus in Sub-Saharan Africa: The Journey So Far and What Remains to Be Done. Journal of Infection and Public Health, 9, 396-307. https://doi.org/10.1016/j.jiph.2015.06.010
[6]
Shapiro, R.L. and Lockman, S. (2010) Mortality among HIV-Exposed Infants: The First and Final Frontier. Clinical Infectious Diseases, 50, 445-447.
https://doi.org/10.1086/649887
[7]
Moges, N.A., Kassa, G.M. and Boneya, D.J. (2017) Rate of HIV Transmission and Associated Factors among HIV-Exposed Infants in Selected Health Facilities of East and West Gojjam Zones, Northwest Ethiopia; Retrospective Cohort Study. BMC Infectious Diseases, 17, 475.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501065/pdf/12879_2017_Article_2578.pdf
[8]
Clayden, P. (2017) Option B+ Malawi. HIV Treatment Bulletin.
http://i-base.info/htb/31787
[9]
Guay, L.A., Musoke, P., Fleming, T., Bagenda, D., Allen, M., Nakabiito, C., Sherman, J., et al. (1999) Intrapartum and Neonatal Single-Dose Nevirapine Compared with Zidovudine for Prevention of Mother-to-Child Transmission of HIV-1 in Kampala, Uganda: HIVNET 012 Randomized Trial. Lancet, 354, 795-802.
https://doi.org/10.1016/S0140-6736(99)80008-7
[10]
World Health Organization (WHO) (2012) Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. WHO, Geneva.
http://apps.who.int/iris/bitstream/handle/10665/70892/WHO_HIV_2012.6_eng.pdf;jsessionid= 809D3D5D3CD096D347166BE55BDE4E8E?sequence=2
[11]
de Ruiter, A., Taylor, G.P., Clayden, P., Dhar, J., Gandhi, K., Gilleece, Y., et al. (2014) British HIV Association Guidelines for the Management of HIV Infection in Pregnant Women 2012 (2014 Interim Review). HIV Medicine, 15, 1-77.
https://doi.org/10.1111/hiv.12185
[12]
UNAIDS (2016) Global AIDS Update.
http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf
[13]
Wonga, V.J., Murray, K.R., Phelpsa, B.R., Vermund, S.H. and McCarraher, D.R. (2017) Adolescents, Young People, and the 90-90-90 Goals: A Call to Improve HIV Testing and Linkage to Treatment. AIDS, 31, S191-S194.
https://doi.org/10.1097/QAD.0000000000001539
[14]
Cohen, M.S., Chen, Y.Q., McCauley, M., Gamble, T., Hosseinipour, M.C., Kumarasamy, N., et al. (2011) Prevention of HIV-1 Infection with Early Antiretroviral Therapy. The New England Journal of Medicine, 365, 493-505.
https://doi.org/10.1056/NEJMoa1105243
[15]
Cameroun (2015) Multiple Indicator Cluster Survey (MICS) 2014 (Enquête par grappe à indicateurs multiples 2014. Rapport de résultats clés.
https://mics-surveys-prod.s3.amazonaws.com/MICS5/West%20and%20Central%20Africa/ Cameroon/2014/Key%20findings/Cameroon%202014%20MICS%20KFR_French.pdf
[16]
Nannozi, V., Wobudeya, E. and Gahagan, J. (2016) Fear of an HIV Positive Test Result: An Exploration of the Low Uptake of Couples HIV Counseling and Testing (CHCT) in a Rural Setting in Mukono District, Uganda. Global Health Promotion, 24, 33-42.
[17]
Wolf, H.T., Halpern-Felsher, B.L., Bukusi, E.A., Agot, K.E., Cohen, C.R. and Auerswald, C.L. (2014) It Is All about the Fear of Being Discriminated [against] … the Person Suffering from HIV Will Not Be Accepted: A Qualitative Study Exploring the Reasons for Loss to Follow-Up among HIV-Positive Youth in Kisumu, Kenya. BMC Public Health, 14, 1154.
https://doi.org/10.1186/1471-2458-14-1154
[18]
Qiao, S., Zhang, Y., Li, X. and Menon, J.A. (2018) Facilitators and Barriers for HIV-Testing in Zambia: A Systematic Review of Multi-Level Factors. PLoS ONE, 13, e0192327. https://doi.org/10.1371/journal.pone.0192327
[19]
Nostlinger, C., Rojas Castro, D., Platteau, T., Dias, S. and Le Gall, J. (2014) HIV-Related Discrimination in European Health Care Settings. AIDS Patient Care and STDs, 28, 155-161. https://doi.org/10.1089/apc.2013.0247
[20]
WHO and UNAIDS (2010) Addressing Violence against Women and HIV/AIDS: What Works?
http://apps.who.int/iris/bitstream/handle/10665/44378/9789241599863_eng.pdf;jsessionid= 09202B82DCA11802635F793DB1D0DAB9?sequence=1
[21]
Branson, B.M., Handsfield, H.H., Lampe, M.A., Janssen, R.S., Taylor, A.W., Lyss, S.B., et al. (2006) Centers for Disease Control and Prevention (CDC). Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings. MMWR Recommendations and Reports, 55, 1-17.
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm
[22]
Henriquez-Camacho, C., Villafuerte-Gutierrez, P., Pérez-Molina, J.A., Losa, J., Gotuzzo, E. and Cheyne, N. (2017) Opt-Out Screening Strategy for HIV Infection among Patients Attending Emergency Departments: Systematic Review and Meta-Analysis. HIV Medicine, 18, 419-429. https://doi.org/10.1111/hiv.12474
[23]
Ngo Nonga, B., Billong, S.C., Thek, P., Mve, V., Tiyou, C., Ambassa, B., et al. (2016) Factors That May Influence Adherence in a University-Based Program for the Prevention of Mother-to-Child Transmission of HIV in Yaoundé-Cameroon. IJTDH, 14, 1-6.
[24]
Dionne-Odom, J., Thomas, K., Welty, T.K., Westfall, A.O., Chi, B.H., Koumavi Ekouevi, D., Kasaro, M., Tih, P.M. and Tita, A.T.N. (2016) Factors Associated with PMTCT Cascade Completion in Four African Countries. AIDS Research and Treatment, 2016, Article ID: 2403936.
[25]
Gugsa, S., Potter, K., Tweya, H., Phiri, S., Sande, O., Sikwese, P., et al. (2017) Exploring Factors Associated with ART Adherence and Retention in Care under Option B+ Strategy in Malawi: A Qualitative Study. PLoS ONE, 12, e0179838.
https://doi.org/10.1371/journal.pone.0179838
[26]
Dalal, S., Johnson, C., Fonner, V., Kennedy, C.E., Siegfried, N., Figueroa, C., et al. (2017) Improving HIV Test Uptake and Case Finding with Assisted Partner Notification Services. AIDS, 31, 1867-1876.
https://doi.org/10.1097/QAD.0000000000001555
[27]
Flax, V.L., Yourkavitch, J., Okello, E.S., Kadzandira, J., Katahoire, A.R. and Munthali, A.C. (2017) If My Husband Leaves Me, I Will Go Home and Suffer, So Better Cling to Him and Hide This Thing: The Influence of Gender on Option B+ Prevention of Mother-to-Child Transmission Participation in Malawi and Uganda. PLoS ONE, 12, e0178298. https://doi.org/10.1371/journal.pone.0178298
[28]
(2008) Malawi, HIV and AIDS. Monitoring and Evaluation Report 2007-2008. National AIDS Commission, Lilongwe.
https://www.google.cm/search?dcr=0&ei=CeN-W-GJAo_cwQKr9pfQBw&q=Malawi+hiv+and+aids +monitoring+and+evaluation+report+2008&oq=Malawi+hiv+and+aids+monitoring+and+ evaluation+report+2008&gs_l=psy-ab.12...455672.499349.0.502607.87.35.0.29.29.0.2265. 5252.5-2j2j9-1.5.0....0...1c.1.64.psy-ab..53.33.5023...0i19k1j33i22i29i30k1j0i22i30k1.0. xDwi5ZGDSts
[29]
Caliari, J.S., Teles, S.A., Reis, R.K. and Gir, E. (2017) Factors Related to the Perceived Stigmatization of People Living with HIV. Revista da Escola de Enfermagem da USP, 51, e03248. https://doi.org/10.1590/s1980-220x2016046703248
[30]
Read, J.S. and Newell, M.K. (2005) Efficacy and Safety of Cesarean Delivery for Prevention of Mother-to-Child Transmission of HIV-1. Cochrane Database of Systematic Reviews, 19, CD005479.
https://www.ncbi.nlm.nih.gov/pubmed/16235405
[31]
Kennedy, C.E., Yeh, P.T., Pandey, S., Betran, A.P. and Narasimhan, M. (2017) Elective Cesarean Section for Women Living with HIV: A Systematic Review of Risks and Benefits. AIDS, 31, 1579-1591.
https://doi.org/10.1097/QAD.0000000000001535
[32]
Snippenburg van, W., Nellen, F.J.B., Smit, C., Wensing, A.M.J., Godfried, M.H. and Mudrikova, T. (2017) Factors Associated with Time to Achieve an Undetectable HIV RNA Viral Load after Start of Antiretroviral Treatment in HIV-1-Infected Pregnant Women. Journal of Virus Eradication, 3, 34-39.
[33]
Read, P.J., Mandalia, S., Khan, P., Harrisson, U., Naftalin, C., Gilleece, Y., et al. (2012) When Should HAART Be Initiated in Pregnancy to Achieve an Undetectable HIV Viral Load by Delivery? AIDS, 26, 1095-1103.
https://doi.org/10.1097/QAD.0b013e3283536a6c
[34]
Hoffman, R.M., Black, V., Technau, K., van der Merwe, K.J., Currier, J., Coovadia, A., et al. (2010) Effects of Highly Active Antiretroviral Therapy Duration and Regimen on Risk for Mother-to-Child Transmission of HIV in Johannesburg, South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54, 35-41.
https://doi.org/10.1097/QAI.0b013e3181cf9979
[35]
Kalua, T., Tippett Barr, B.A., van Oosterhout, J.J., Mbori-Ngacha, D., Schouten, E.J., Gutpa, S., et al. (2017) Lessons Learned from Option b+ in the Evolution toward “Test and Start” from Malawi, Cameroon, and the United Republic of Tanzania. JAIDS Journal of Acquired Immune Deficiency Syndromes, 75, S43-S50.
https://doi.org/10.1097/QAI.0000000000001326
[36]
Shouten, E., Jahn, A., Chimbwandira, F., Harries, A.D. and Van Damme, W. (2013) Is Option B+ the Best Choice. The Lancet, 381, 1272-1273.
https://doi.org/10.1016/S0140-6736(13)60833-8
[37]
Chung, M.H., Kiarie, J.N. and Barbra, A. (2008) Highly Active Antiretroviral Therapy (HAART) versus Zidovudine/Nevirapine Effects on Early Breast Milk HIV-1 RNA: A Phase II Randomized Clinical Trial. Antiviral Therapy, 13, 799-807.
[38]
Darak, S., Darak, T., Kulkarni, S., Kulkarni, V., Parchure, R., Hutter, I., et al. (2013) Effect of Highly Active Antiretroviral Treatment (HAART) during Pregnancy on Pregnancy Outcomes: Experiences from a PMTCT Program in Western India. AIDS Patient Care STDS, 27, 163-170. https://doi.org/10.1089/apc.2012.0401
[39]
Njom Nlend, A.E., Nga Motazé, A., Moyo Tetang, S., Zeudja, C., Ngantcha, M. and Tejiokem, M. (2016) Preterm Birth and Low Birth Weight after in Utero Exposure to Antiretrovirals Initiated during Pregnancy in Yaoundé, Cameroon. PLoS ONE, 11, e0150565. https://doi.org/10.1371/journal.pone.0150565
